New study reveals crucial protein interactions in Duchenne Muscular Dystrophy, opening doors to more precise and effective ...

Exciting news in the biotech industry as positive phase 2 results for sevasemten in BMD drive long-term investment potential ...

Study results provide root explanations for how dystrophin functions on a molecular level, providing base-level insights into ...

On their family farm in rural Illinois, the Flessner boys have free range. But early on, something was holding older brother ...

From imaging innovations to new treatment approvals, 2024 brought advancements in Duchenne muscular dystrophy care and ...

Columnist Shalom Lim appreciates how Duchenne never offers a dull moment as he prepares for the challenges and adventures in ...

A groundbreaking study has shed light on the complex interactions between dystrophin, a protein critical to muscle stability, and its partner protein, dystrobrevin, offering new pathways for ...

Satralizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Duchenne Muscular Dystrophy.

An advanced centre for treating muscular dystrophy will soon be established at Chacha Nehru Children’s Hospital. The decision ...

Dec. 16, 2024 — A novel drug holds promise for treating Duchenne muscular dystrophy (DMD), a rare genetic disorder that causes severe muscle degeneration. Researchers have discovered that an ...

Department of Health (DoH) of Hong Kong approved AGAMREE® for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 4 years and older Follows recent approval from China’s National ...